← Back to headlines
Neurocrine to Acquire Soleno in $2.9 Billion Transaction
Neurocrine Biosciences has announced its intention to acquire Soleno Therapeutics in a transaction valued at $2.9 billion.
Sources
Showing 0 of 1 sources
No articles available in your preferred languages.
1 article available in other languages below.
Related Stories
The OLB Group Reports Q2 Financials; FinVolution Group to Announce Results
44m ago
Mark Cuban and Tech Founders Oppose California Wealth Tax Proposal
4h ago
Greece to Save €2 Billion by Early Debt Repayment in 2026
4h ago
SEC Proposal Would Allow Companies to Announce Earnings Quarterly, Ditch Filings
5h ago